We would love to hear your thoughts about our site and services, please take our survey here.
Don’t listen to Porky’s lack of accounting and auditing knowledge. Just because an audit is happening doesn’t force the legal system to work faster, so there is no certainty this will be resolved by the new reporting date. It will be recorded as the auditors see most appropriate, likely with contingent liabilities included. What do you think happens with legal disputes that drag on for years? They don’t do audits?
The 99% specificity jarred me as I was expecting 100%. I know this was only on 102 samples so could be much higher or lower in real world mass testing, but if the UK is testing 2m/day, that is 20,000 false positives, every day. 600,000 a month. I am not sure it will be the sovereign test given current prevalence rates.
Maybe rotate the tests through? Mologic between waves, AVCT during waves? Mologic mass screening, AVCT for large events?
I am not sure either can be the sole, sovereign test based on currently available numbers.
Not entirely true, only part of a framework agreement. No orders or contracts yet.
10Guitars, you do realise that the only reason NCYT made it to such lofty heights was new people buying in? How do you think AIM works? For you to exit, someone needs to buy. Are you saying GM doesn’t owe them any duty of care, because they bought at £12 instead of 50p?
Been over this a hundred times. Colin King has never said, implied, winked, nodded, scratched his nose, giving away that Mologic are not being considered for the sovereign test. There was one email, one time, to one PI, saying that Omega would be making the Mologic test as Visitect as well as the DHSC selected test.
If I put it another way: “I am going to the chippy, getting myself some chips as well as my other half’s order.” She couldn’t possibly order chips as well could she based on that sentence? Of course she could you muppets.
If you want to maintain it may not be Mologic and you believe it to be AVCT on other grounds, fine, but please give this line of flawed reasoning a rest.
I think the opportunity off the back of any Mologic test will revolve around private sales. If it gets good PR, particular through NIH, it carries weight for employers to use on employees.
Glenfiddich 15 for me as my drinking scotch, Glenfarclas 25 for special occasions. Maybe a Cohiba if it’s a really special occasion.
Agray - IMO you are correct it is not going to be ODX’s ‘Visitect’ test as a sovereign test, but the same test submitted by Mologic is on the cards.
And I think you have stated what most people miss.
ODX could produce 1M Visitect tests, and 1M ‘Sovereign/Mologic’ tests (hypothetically obviously) and they would be reported that way, but only real difference would be the packaging. I think reading into an email that split out production lines as confirmation AVCT have won the ‘race’ is simply fantasy. It would be split out no matter which test was chosen.
I don’t want to stir anything up and make this an ODX conversation, hopefully the above is useful to someone as it’s very misleading. BTW, I do think AVCT will be hugely successful and will be chosen, based mainly on S/S figures (please forget THAT email, it’s worthless unless you are in ODX). Having sold my first lot at £1.80 for a small profit, I bought back in last week and am now holding 800 shares at a £2.61 average. The last of my spare capital.
GLA
The more I read from you Goldtrig the more my ‘ad hominem’ was justified... I don’t think it was an ad hominem as I attacked the thought rather than the person, but nevertheless I apologise as it wasn’t helpful.
Let’s say you are right that Paul does know. What do you want him to say in that reply about allocation split?
“Omega will produce 2m/week of Mologic’s tests. 1m for the government under NHS branding, 1m under Visitect.”
Of course not, he can’t. He can only comment on what he is allowed, and that is that ODX will produce Visitect irrespective of outcome.
The outcome is way too sensitive to give even a hint. You are reading into something that doesn’t exist.
I am off to bed now, hopefully this thread will be buried before I check back sometime tomorrow.
Night all.
I’ll tell you that you are both wrong. There is nothing to read or comprehend when it comes to who’s test ODX will manufacture. Paul McManus will not know, so reading into an email about capacity allocation from him is as good as reading tea leaves. Nothing to see here. Leave it alone. Debate something useful.
Ps. Hypothesis means: a supposition or proposed explanation made on the basis of limited evidence as a starting point for further investigation.
Proposed explanation and starting point being key.
As dumb as your first post.
Prove what? That something doesn’t exist?
I DO think the most likely explanation behind everything (TT, delay to May, etc.) is that AVCT strips will be used and they are still tweaking, or are combining the two (AVCT and Mologic) into a single test. I think the delays will give Mologic’s original test a chance though as we cannot wait for AVCT indefinitely, but is an outside chance as the AVCT CEO is notably more confident in timeframes. To think Paul McManus has the answers ahead of DHSC though, and has shared this information via an email, and that is ‘proof’, is dumbest thought I’ve read day.
But that’s not the case anymore is it? We have been awarded a contract with a profitable minimum.
Not sure why that is surprising TWatcher?
Yes _TCO, that’s my understanding. ODX do nothing, they still get £50m. I thought there would have to be something like that as we have sold manufacturing capacity rather than a product, and surely wouldn’t be incurring all of the associated overheads without any guaranteed income.
I am confident we will hit the maximum value of the contract, only question is whether it covers 1 or 2 years...
DHSC will take 104m tests/year. 8.666m/month. No way we are getting a contract that equates to 57p/test. Is going to be much, much more.
This is just one distributor so I wouldn’t get too far ahead of myself. Nevertheless is nice to see demand confirmed, though never expected anything else.
I should add “based on timeframes provided/implied by ODX/CK”.
Good morning all,
Just been thinking about the length of time TT is taking, and wondering if it is possible ODX have already done everything (run the batches, submitted to Mologic, etc.), but Mologic are just slow walking us in the final sign-off? I imagine that might be done pending some sort of announcement by Boris that the UK has produced three world beating tests, manufactured locally to support our world beating NHS, you get the picture, but feel that is grasping at straws... Being held at Mologic would also mean ODX can maintain TT is ‘ongoing’ and don’t have to issue an RNS.
I am really just sound boarding other possible scenarios as I am at the point where I don’t believe it is genuinely ‘ongoing’ unless our first (and possibly second) batches didn’t cut it.
Have a good weekend!